CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production
© Cutolo et al.; licensee BioMed Central Ltd. 2009
Received: 28 March 2009
Accepted: 23 November 2009
Published: 23 November 2009
Co-stimulatory signal B7(CD80/CD86):CD28 is needed in order to activate T cells in immune response. Cytotoxic T lymphocyte-associated antigen-4-immunoglobulin (CTLA4-Ig) binding to the B7 molecules on antigen-presenting cells downregulates this activation and represents a recent biological treatment in rheumatoid arthritis (RA). Objectives of the study were to investigate the presence of the B7.2 (CD86) molecule and its masking by CTLA4-Ig on cultures of both RA synovial macrophages (RA SM), and of macrophages differentiated from THP-1 cells (M). In addition, the anti-inflammatory effects of CTLA4-Ig on co-cultures of RA SM and M with activated T cells were tested.
All macrophages were co-cultured for 24 hours with activated T cells, without or with CTLA4-Ig (10, 100, 500 μg/ml for 1 hour, 3 hours and overnight, respectively). Immunofluorescence (IF) staining for B7.2, and an analysis of inflammatory cytokine expression (interleukin (IL) -6, tumor necrosis factor (TNF) α, IL-1β, transforming growth factor (TGF) β) by immunocytochemistry (ICC), western blot (WB) and reverse transcriptase-polymerase chain reaction (RT-PCR) were performed.
Macrophages showed intense B7.2 expression. CTLA4-Ig/B7.2 masking was evident for all macrophages, even after only 1 hour of cell culture (range from 10 to 100 μg/ml). ICC of co-cultures showed a dose-dependent decrease in inflammatory cytokines (P < 0.001 for IL-6, TNFα, IL-1β and TGFβ). Data were confirmed by WB and RT-PCR analysis.
Optimal concentrations of CTLA4-Ig for the CTLA4-Ig/B7.2 masking on activated macrophages were identified and were found to induce significant downregulation in the cell production of IL-6, TNFα, IL1-β and TGFβ. In conclusion, macrophages would appear to be a sensitive target for CTLA4-Ig treatment in RA.
Rheumatoid arthritis (RA) is a prototype of an immune-mediated chronic inflammatory disease and is considered a model for studying and validating new targeted biological therapies.
Migration of activated lymphocytes and monocytes into the synovial tissue in RA is one of the first steps in synovial inflammation, followed by subsequent damage of other joint components [1–3]. In recent years, the role of T cells has regained some importance in the immunopathology of RA, thus providing a rationale for the specific targeting of T cells with biologic treatments [4–8].
T cell response is triggered by an initial signal delivered through the T cell receptor (TCR), and it recognizes the antigenic peptide within the context of the major histocompatibility complex (MHC) molecule on the antigen-presenting cells (APC). In order to be fully activated, it needs to be followed by another signal, which is provided by the signals of the co-stimulatory molecules that are expressed on APC (such as dendritic cells, B-lymphocytes and macrophages) .
Among the known multiple co-stimulatory signals, one of the best described is the CD80/CD86:CD28 pathway [10, 11]. CD80 (B7.1) and CD86 (B7.2), which are expressed on APC, bind the CD28 molecule on the T cells, thereby transducing the co-stimulatory signal in the early phase of the immune response. However, the activated T cells then express the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) molecule, which binds the B7 molecules on APC with a 10- to 20-fold greater affinity compared with CD28, and downregulates the T cell activation [12–14].
CTLA-4-Ig, a biological agent, is constructed by genetically fusing the external domain of human CTLA-4 and a fragment of the Fc domain of human immunoglobulin G1 (IgG1), which has been modified to be non-complement fixing. Like the native CTLA-4, the fusion protein (CTLA-4-Ig) binds more avidly to CD80/CD86 (APC) than to CD28 (T cells), thus interfering with CD28/B7 interaction [15, 16].
Therefore, taking these mechanisms into consideration, several randomized, double-blind, placebo-controlled clinical trials have demonstrated that CTLA-4-Ig improves the signs and symptoms of RA in patients with inadequate response to methotrexate or/and anti-TNF agents [17–20].
However, because macrophages play a crucial role in various steps of the synovial RA pathophysiology, the aim of this in vitro study was firstly, to search for the presence of the B7.2 molecule on the surface of cultured synovial macrophages (SM) obtained from active RA patients, and then to investigate the modulatory effects of CTLA-4-Ig in a co-culture of RA SM or macrophages together with an activated T cell line . In particular, the investigation focused on the effects of CTLA-4-Ig on the production of peculiar mediators of inflammation produced by macrophages, such as cytokines (IL-6, TNFα, IL-1β) and transforming growth factor beta (TGFβ).
Materials and methods
Rheumatoid arthritis synovial macrophages (RA SM) cultures
RA SM were obtained from seven patients (five females and two males, mean age: 47 ± 12 years, disease duration 4 ± 6 years, Disease Activity Score using 28 joint counts (DAS28) >5.2) who fulfilled the 1987 revised criteria of the American College of Rheumatology for adult RA and who underwent therapeutic arthroscopic synoviectomy or knee replacement surgery.
At the time of surgery, all patients had been taking non-steroidal anti-inflammatory drugs for 20 days and low-dose glucocorticoids (prednisone range 5 to 7.5 mg/day) for three or four months. No intra-articular treatments, systemic biological drugs, antiproliferative drugs or other disease modifying anti-rheumatic drugs (DMARDs) were being administered at the time of knee surgery, nor had they been for at least four months prior to it. The Ethics Committee of the University of Genova approved the study and informed consent was obtained from all patients.
After surgery, the synovial RA tissue samples were carefully cut into small pieces (2 to 5 mm), washed in Dulbecco's phosphate buffered saline (DPBS; Sigma-Aldrich, Sigma Chemical Division, Milan, Italy) and incubated in collagenase (0.75 mg/ml; type IV from Clostridium histolyticum; Sigma-Aldrich, Sigma Chemical Division, Milan, Italy) for one hour at 37°C. The digest was passed through a pore size 58 Å ~150 mesh wire to separate the synovial cells from the debris tissue. The cells were then washed three times with DPBS, resuspended in RPMI-1640 medium (Sigma-Aldrich, Sigma Chemical Division, Milan, Italy) that had been supplemented with 10% fetal bovine serum (containing < 0.5 EU/ml endotoxin), 2 mmol/l L-glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin (Sigma-Aldrich, Sigma Chemical Division, Milan, Italy). Viability of the cells (90 to 95%) was tested by trypan blue exclusion.
The synovial cells were seeded into flexiperm chamber slides (International, PBI S.p.a. Milan, Italy; 105 cells/well) and cultured in 5% CO2 air humidified atmosphere at 37°C. After one hour, non-adherent cells were washed out, while adherent cells (RA SM) were incubated in culture medium in the presence or in the absence of lipopolysaccharide (LPS) stimulus (10 μg/ml) for one hour to investigate B7.2 expression .
B7.1 expression was not tested because it is expressed in lower amounts on resting cells and is only upregulated with prolonged T cell stimulation, while B7.2 is constitutively expressed and rapidly upregulated on APC with an antigen-specific signal, thus indicating that B7.2 is chiefly involved in mediating initial T cell activation [10, 23].
EBV+ transfected human B-lymphocytes were also incubated in flexiperm chamber slides as a positive cell line control for B7.2 expression.
THP-1 cell-line cultures
THP-1 (cell bank. Interlab Cell Line Collection. Clinical Pathology Dept, IST, Genova, Italia) human monocytes were incubated with phorbol myristate acetate (PMA; 0.5 μg/ml) for two hours to differentiate into macrophages, then cells were seeded into flexiperm chamber slides (International, PBI S.p.a. Milan, Italy; 105 cells/well) and cultured in 5% CO2 air humidified atmosphere at 37°C.
Macrophage and T cell co-cultures
The macrophages that were obtained from THP-1 as previously described, were co-cultured with human T cells for 24 hours (Jurkat T cells previously activated with concanavalin-A (5 μg/ml) for 20 hours). They were then seeded into multiwell flat bottom plates both in the absence and the presence of various concentrations of CTLA-4-Ig (10, 100, 500 μg/ml). The macrophage/T cell ratio was 1:1.
At the end of the co-culture incubation period, the T cells were removed with several washes in PBS. Macrophages were harvested, washed in PBS, and used for the various assays. Preliminary immunocytostaining using a specific monoclonal antibody to identify the macrophages (anti-human HAM56, Dako, Carpinteria, CA, USA) was performed. All experiments were performed in triplicate.
RA SM that had been isolated from synovial tissue as previously described, were co-cultured into multiwell flat bottom plates with T cells (Jurkat T cells previously activated with concanavalin-A (5 μg/ml) for 20 hours) for 24 hours, both in the absence and presence of CTLA-4-Ig at various concentrations (100, 500 μg/ml). The in vitro CTLA-4-Ig concentrations to be tested were chosen on the basis of the available literature, suggesting values that are very close to the therapeutic doses used to treat RA [22, 24, 25]. The macrophage/T cell ratio was 1:1.
At the end of the co-culture incubation period, the T cells were removed with several washes in PBS. The RA SM were harvested, washed in PBS, and used for the various test assays. In order to identify macrophages, we performed preliminary immunocytostaining with a specific monoclonal antibody (anti-human HAM56, Dako, Carpinteria, CA, USA). All experiments were performed in triplicate.
Slides with cellular spots obtained from cultures of macrophages were seeded into flexiperm chamber slides, then fixed in acetone for 30 seconds, air dried, and rehydratated in PBS. The spots were then incubated with an fluorescein isothiocyanate anti-human CD86 (B7.2) mouse antibody (BD, Biosciences, New York, NY, USA) at room temperature for 45 minutes, washed in PBS, and cover slipped with glycerol medium. Evaluation of the fluorescence expression for CD86 (B7.2) was performed by fluorescence microscopy (Leica, Cambridge, UK).
Macrophages from co-cultures that had been seeded into multiwell flat bottom plates were harvested mechanically and incubated on glass slides for 45 minutes at 4°C, then the cellular spots were fixed in acetone for 30 seconds, air dried, and stored at -20°C until use.
After rehydration in PBS, the slides were incubated in a 3% H2O2 solution for 15 minutes at room temperature to prevent non-specific reaction due to endogenous peroxidases.
The spots were then incubated with anti-cytokine (anti-IL6, anti-TNFα, anti-IL-1β) and anti-TGFβ monoclonal antibodies (all diluted 1:100 at room temperature for 45 minutes. Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Linked antibodies were detected by a biotinylated universal (pan-specific) antibody and subsequently by horseradish peroxidase streptavidin (Vector Laboratories, Burlingame, CA, USA). Each step was followed by two washes in PBS. The staining reaction was developed by the diaminobenzidine system (DakoCytomation, Dako North America, Inc., Carpinteria, CA, USA). Finally, slides were counter-stained with hematoxylin, fixed with ethanol, and cover-slipped with Eukitt mounting medium for microscope preparations (O. Kindler GmbH, Friburg, Germany). Negative controls were treated the same way, except that the primary antibodies were omitted.
Image analysis of immunocytochemistry slides was performed using the Leica Q-Win image analysis system (Leica, Cambridge, UK). Approximately 100 cells were analysed for each sample, and pixels/mm2 (positive area) were quantified by the Leica Q-Win software (Leica, Cambridge, UK). The individual cells were randomly selected by the operators using the cursor and were then automatically measured as positive areas.
Immune enzymatic assay (ELISA)
After 24 hours of treatment, the culture medium was harvested and stored at -20°C until analysis. The enzymatic immunoassay for quantitative determination of IL-6, TNFα and IL-1β was carried out with a microplate kit system (Diaclone, Besançon, France). The results were obtained with a multiwell plate automatic processor (Techno Genetics, Milan, Italy).
Western blot analysis
After the various treatments, macrophage pellets were lysed in a buffer containing 20 mmol/l Tris-HCl pH 8, 150 mmol/l NaCl, 1 mmol/l phenylmethylsulphonyl fluoride, 5 mg/ml aprotinin, and 0.5% Nonidet P-40 (Promega, Milan, Italy) for one hour at 4°C. The lysates were then centrifuged for 10 minutes at 13,000 rpm. Protein samples (20 mg) were diluted with sample buffer and separated by 10% SDS-PAGE. The proteins were transferred to a Hibond-C nitrocellulose membrane (GeHealthCare Europe, Friburg, Germany), after which the membrane was blocked for one hour at room temperature in PBS containing 5% non-fat powdered milk.
To carry out immunoblot analysis, the membrane was incubated with rabbit anti-IL-6 (diluted 1:500), goat anti-TNFα (1:200) and goat anti-TGFβ (1:200) antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Then membranes were washed in 1% PBS + 0.05% Tween 20, pH 7.4 and incubated for one hour at room temperature with a secondary anti-rabbit antibody for IL-6 (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and a secondary anti-goat antibody for TNFα and TGFβ (1:65,000; Sigma, Milan, Italy). After three further washes with PBS/Tween, a bound secondary antibody was detected through emitting chemiluminescent reaction (Immobilon, Millipore, CA, USA).
Western blot analysis was not performed on RA SM because it would have been difficult to obtain enough cells from the primary culture to allow full analysis of the cytokines being investigated.
Densitometry analysis of the western blot bands were performed by Delta Sistemi Analysis Software (version 3.0.02, Latina, Italy).
Reverse transcriptase-polymerase chain reaction
mRNA extraction from the various experimental conditions of macrophage/Jurkat co-cultures was performed with the Rneasy Mini Kit (Qiagen, Valencia, CA, USA).
The samples were analysed by RT-PCR, using both IL-6-, TNFα-, TGFβ-specific primers (Invitrogen S.R.L., Milan, Italy) and beta-actin-specific primers (Promega, Milan, Italy) as the internal positive control. Statistical analysis was carried out by the non-parametric Wilcoxon T test.
Statistical analysis was performed to compare the paired treatments. P < 0.05 was considered statistically significant.
B7.2 (CD86) positivity on cultured macrophages
In vitroCTLA-4-Ig/B7.2 masking on macrophages
Analysis by both fluorescence and optic microscopy in light field showed a reduction of B7.2 positivity on macrophages treated with CTLA-4-Ig, certainly due to CTLA4-Ig binding to B7.2 and subsequent B7.2 expression masking.
Effects of CTLA-4-Ig on cytokine expression in macrophage and T cell co-cultures
The changes that were observed in IL-6, TNFα and TGFβ expression included a significant, dose-dependent decrease (P < 0.001), following treatment with CTLA-4-Ig at both 100 and 500 μg/ml. IL-1beta expression only showed a significant decrease for CTLA-4-Ig (500 μg/ml) treatment (P < 0.001). Interestingly, as compared with untreated macrophages (controls), we found a significant decrease (P < 0.05) which was limited to TNFα expression, even after administering only 10 μg/ml of CTLA-4-Ig (Figures 3e to 3h).
TGFβ did not show any change in expression following the addition of CTLA-4-Ig (range from 100 to 500 μg/ml) compared with untreated RA SM (controls; data not shown).
The current report is the first to describe the positivity for the B7.2 co-stimulatory molecule in RA SM and its interaction with the CTLA-4 competitor (CTLA-4-Ig).
Earlier studies had already detected the B7.2 molecule within the RA synovial tissue (while B7.1 was found to be almost altogether absent), and particularly so in areas enriched with CD68-positive macrophages, such as the lining layer and close to CD3-positive T cells . However, the real implications of this observation were not determined at that time. Researchers merely believed that it suggested the presence of important therapeutic targets, such as co-stimulatory molecules (B7 complex), in the synovial tissue, at least as far as the early intervention on the immune response in RA was concerned.
The present study shows that the CTLA-4-Ig fusion protein is able to downregulate SM activation (co-cultured with T cells) by interacting with the B7.2 molecule expressed on their surface and by decreasing their production of inflammatory RA cytokines (IL-6, TNFα, IL-1β).
Furthermore, for the first time, the present study shows that CTLA4-Ig treatment reduces the expression of TGFbeta in human macrophages.
Recent reports suggest that TGFβ-induced effects have an autocrine pathogenetic importance in RA; for example, in inducing matrix metalloproteinase-mediated matrix degradation/remodeling. It has also been suggested that in the context of an inflammatory cytokine milieu, TGFβ supports de novo differentiation of IL-17-producing T cells. Therefore, these observations may be strengthened by the present results [26, 27].
Finally, we must now consider SM as possible direct targets of CTLA-4-Ig-mediated downregulation. As a matter of fact, current concepts suggest that inhibiting T cell co-stimulation is the key mode of CTLA-4 action.
However, additional mechanisms of action may be related to the fact that CTLA-4 directly binds to APC (such as macrophages) and might directly modulate their function. Thus, CTLA-4 might not only indirectly affect T cell interaction with APC, but CTLA-4 may also directly affect its primary cellular target, which is the cells of the monocytic lineage (i.e. macrophages) that strongly express the B7-2 molecule (CD86) in RA synovial tissue.
As is well known, macrophages are not only one of the main inflammatory cytokine-producing cells in the RA synovial tissue, but they also differentiate into bone resorbing osteoclasts, which are implicated in RA inflammatory bone erosions and joint damage [28, 29]. Recently, it was found that CTLA-4-Ig directly inhibits the Receptor Activator for Nuclear Factor k B Ligand (RANKL) - as well as the TNFα-mediated osteoclastogenesis in vitro in a dose-dependent manner (which is clearly evident and significant at 100 μg/ml), without the need for the concomitant presence of T cells .
Furthermore, CTLA-4-Ig was effective at inhibiting the TNF-induced osteoclast formation in a non-T cell-dependent TNF-induced model of arthritis, as well as at inhibiting the formation of inflammatory bone erosions in vivo .
Therefore, even if CTLA-4-Ig typically works by inhibiting T cell co-stimulation and T cell activation, we must now consider that a further primary cellular target of CTLA-4-Ig might also be mononuclear APC, such as SM that express the B.7 complex.
Although we co-cultured macrophages with T cells, the results clearly suggest direct downregulation of the CTLA-4-Ig fusion protein on the RA SM pro-inflammatory function. The next step is to test these effects on SM monocultures.
Interestingly, recent concepts, such as reverse signalling, have defined that the cell-cell interactions can be rather bidirectional, which means that the 'ligand'-expressing cell (i.e. macrophage) undergoes a functional change upon engaging with the receptor . For example, the binding of CTLA-4 to its ligand B7 might lead to a functional change in APC, as already observed [32, 33].
A different approach was previously used to study the role of the CTLA-4 molecule in the inflammatory reaction of RA joints. It involved blocking CTLA-4 with an anti-CTLA-4 antibody and then assessing its effects on TNFα and IL-1 production in synovial fluid mononuclear cell cultures . As expected, adding the anti-CTLA-4 antibody enhanced TNFα and IL-1 production in a dose-dependent manner.
In conclusion, the CTLA-4-Ig interaction we observed with SM and their subsequent downregulation further support the key role they play in various steps of RA, and may explain the beneficial effects of CTLA-4-Ig fusion protein treatment in controlling the signs and symptoms of RA, even in advanced phases of the disease.
cytotoxic T lymphocyte-associated antigen-4
disease-modifying antirheumatic drugs
Dulbecco's phosphate buffered saline
enzyme-linked immunosorbent assay
major histocompatibility complex
phorbol myristate acetate
reverse transcriptase-polymerase chain reaction
T cell receptor
transforming growth factor
tumor necrosis factor.
The study was partially supported by a research grant from Bristol-Myers Squibb Company (In Vitro Study IM 101-157/11.07.2007), who also provided the CTLA-4-Ig molecule.
- Lundy SK, Sarkar S, Tesmer LA, Fox DA: Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis Res Ther. 2007, 9: 202-10.1186/ar2107.PubMed CentralView ArticlePubMedGoogle Scholar
- Brennan FM, McInnes JIB: Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008, 118: 3537-3545. 10.1172/JCI36389.PubMed CentralView ArticlePubMedGoogle Scholar
- Cutolo M, Straub RH, Bijlsma JW: Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol. 2007, 3: 627-634. 10.1038/ncprheum0601.View ArticlePubMedGoogle Scholar
- Cope AP, Schulze-Koops H, Aringer M: The central role of T cells in rheumatoid arthritis. Clin Exp Rheumatol. 2007, 25: S4-11.PubMedGoogle Scholar
- Miossec P: Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium. Arthritis Res Ther. 2008, 10: S2-10.1186/ar2413.PubMed CentralView ArticlePubMedGoogle Scholar
- Olsen NJ, Stein MC: New drugs for rheumatoid arthritis. N Engl J Med. 2004, 350: 2167-2179. 10.1056/NEJMra032906.View ArticlePubMedGoogle Scholar
- Abbott JD, Moreland LW: Rheumatoid arthritis: Developing pharmacological therapies. Expert Opin Investig Drugs. 2004, 13: 1007-1018. 10.1517/135437184.108.40.2067.View ArticlePubMedGoogle Scholar
- Mariette X: Emerging biological therapies in rheumatoid arthritis. Joint Bone Spine. 2004, 71: 470-479. 10.1016/j.jbspin.2004.07.008.View ArticlePubMedGoogle Scholar
- Goronzy JJ, Weyand CM: T-cell co-stimulatory pathways in autoimmunity. Arthritis Res Ther. 2008, 10: S3-10.1186/ar2414.PubMed CentralView ArticlePubMedGoogle Scholar
- Trikudanathan S, Sayegh MH: The evolution of the immunobiology of co-stimulatory pathways: clinical implications. Clin Exp Rheumatol. 2007, 25: S12-21.PubMedGoogle Scholar
- Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G, Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahlman I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B, Nutland S, Rance HE, Everettt V, Smink LJ, Lam AC, Cordell HJ, Walzer NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, et al: Association of the T-cell regulatory gene CTLA-4 with susceptibility to autoimmune disease. Nature. 2003, 423: 506-511. 10.1038/nature01621.View ArticlePubMedGoogle Scholar
- Walunas TL, Lenschow DJ, Bakker CY, Linsley PS, Freeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994, 1: 405-413. 10.1016/1074-7613(94)90071-X.View ArticlePubMedGoogle Scholar
- Alegre ML, Frauwirth KA, Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 2001, 1: 220-228. 10.1038/35105024.View ArticlePubMedGoogle Scholar
- Leibson PJ: The regulation of lymphocyte activation by inhibitory receptors. Curr Opin Immunol. 2004, 16: 328-336. 10.1016/j.coi.2004.03.006.View ArticlePubMedGoogle Scholar
- Alten R, Bosch Van den F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I, Becker JC: Co-stimulatory blockade in patients with rheumatoid arthritis: A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4-Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 2002, 46: 1470-1479. 10.1002/art.10294.View ArticlePubMedGoogle Scholar
- Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker JC, Hagerty DT, Moreland LW: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA-4Ig. N Engl J Med. 2003, 349: 1907-1915. 10.1056/NEJMoa035075.View ArticlePubMedGoogle Scholar
- Malstrom V, Trollmo C, Klareskog L: Modulating co-stimulation: A rational strategy in the treatment of rheumatoid arthritis?. Arthritis Res Ther. 2005, 7: S15-20. 10.1186/ar1505.View ArticleGoogle Scholar
- Buch MH, Vital EM, Emery P: Abatacept in the treatment of rheumatoid arthritis. Arthritis Res Ther. 2008, 10: S5-10.1186/ar2416.PubMed CentralView ArticlePubMedGoogle Scholar
- Rozelle AL, Genovese MC: Efficacy results from pivotal clinical trials with abatacept. Clin Exp Rheumatol. 2007, 25: S30-34.PubMedGoogle Scholar
- Michaud K, Bombardier C, Emery P: Quality of life in patients with rheumatoid arthritis: Does abatacept make a difference?. Clin Exp Rheumatol. 2007, 25: S35-45.PubMedGoogle Scholar
- Cutolo M, Capellino S, Montagna P, Sulli A, Seriolo B, Villaggio B: Anti-inflammatory effects of Leflunomide in combination with methotrexate on co-culture of T lymphocytes and synovial macrophages from rheumatoid arthritis patients. Ann Rheum Dis. 2006, 65: 728-735. 10.1136/ard.2005.045641.PubMed CentralView ArticlePubMedGoogle Scholar
- Goodier MR, Londei M: Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA-4-Ig. Immunology. 2001, 102: 15-23. 10.1046/j.1365-2567.2001.01147.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND: Differential expression of the co-stimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue. Br J Rheumatol. 1996, 35: 33-37. 10.1093/rheumatology/35.1.33.View ArticlePubMedGoogle Scholar
- Thomas R, Quinn C: Functional differentiation of dendritic cells in rheumatoid arthritis. Role of the CD86 in the synovium. J Immunol. 1996, 156: 3074-3086.PubMedGoogle Scholar
- Gao YH, Wang P, Takagi K, Shimozato O, Yagita H, Okigaki T, Matasumura M: Expression of a soluble form of CTLA-4 on macrophage and its biological activity. Cell Research. 1999, 9: 189-199. 10.1038/sj.cr.7290017.View ArticleGoogle Scholar
- Pohlers D, Beyer A, Koczan D, Wilhelm D, Thiesen HJ, Kinne RW: Constitutive upregulation of the transforming growth factor-β pathway in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 2007, 9: R59-10.1186/ar2217.PubMed CentralView ArticlePubMedGoogle Scholar
- Mangan PR, Harrington LE, Quinn DB, Helms WS, Bullard DC, Elson CO, Hatton RD, Wahl SM, Schoeb TR, Weaver CT: Transforming growth factor-beta induces development of the T(H)17 lineage. Nature. 2006, 441: 231-234. 10.1038/nature04754.View ArticlePubMedGoogle Scholar
- Teitelbaum SL: Bone resorption by osteoclasts. Science. 2000, 289: 1504-1508. 10.1126/science.289.5484.1504.View ArticlePubMedGoogle Scholar
- McInnes IB, Schett G: Cytokines in rheumatoid arthritis. Nat Rev Immunol. 2007, 7: 429-442. 10.1038/nri2094.View ArticlePubMedGoogle Scholar
- Axmann R, Herman S, Zaiss M, Franz S, Polzer K, Zwerina J, Herrmann M, Smolen J, Schett G: CTLA-4 directly inhibits osteoclast formation. Ann Rheum Dis. 2008, 67: 1603-1609. 10.1136/ard.2007.080713.View ArticlePubMedGoogle Scholar
- Alegre ML, Fallarino F: Mechanisms of CTLA-4-Ig in tolerance induction. Curr Pharm Des. 2006, 12: 149-160. 10.2174/138161206775193046.View ArticlePubMedGoogle Scholar
- Fallarono F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P: Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003, 4: 1206-1212. 10.1038/ni1003.View ArticleGoogle Scholar
- Grohmann U, Orabona C, Fallarono F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol. 2002, 3: 1097-1101. 10.1038/ni846.View ArticlePubMedGoogle Scholar
- Liu MF, Yang CY, Li JS, Lai KA, Chao SC, Lei HY: Increased expression of down-regulatory CTLA-4 molecule on T lymphocytes from rheumatoid synovial compartment. Scand J Immunol. 1999, 50: 68-72. 10.1046/j.1365-3083.1999.00565.x.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.